MX2017014257A - Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t. - Google Patents

Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t.

Info

Publication number
MX2017014257A
MX2017014257A MX2017014257A MX2017014257A MX2017014257A MX 2017014257 A MX2017014257 A MX 2017014257A MX 2017014257 A MX2017014257 A MX 2017014257A MX 2017014257 A MX2017014257 A MX 2017014257A MX 2017014257 A MX2017014257 A MX 2017014257A
Authority
MX
Mexico
Prior art keywords
barr virus
methods
cell therapy
ebv
lymphoproliferative disorders
Prior art date
Application number
MX2017014257A
Other languages
English (en)
Other versions
MX386334B (es
Inventor
DOUBROVINA Ekaterina
John O'REILLY Richard
Elizabeth Prockop Susan
Nasreen Hasan Aisha
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56027234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017014257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017014257A publication Critical patent/MX2017014257A/es
Publication of MX386334B publication Critical patent/MX386334B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen métodos de tratamiento de un EBV-LPD (trastorno linfoproliferativo asociado al virus de Epstein-Barr) en un paciente humano que ha fallado a la quimioterapia de combinación para el tratamiento de EBV-LPD y/o la terapia de radiación para tratar el EBV-LPD, que comprende administrar el paciente humano una población de células T alogénicas que comprenden células T específicas de EBV.
MX2017014257A 2015-05-12 2016-05-11 Cèlulas t y sus usos en el tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr. MX386334B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160549P 2015-05-12 2015-05-12
PCT/US2016/031784 WO2016183153A1 (en) 2015-05-12 2016-05-11 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Publications (2)

Publication Number Publication Date
MX2017014257A true MX2017014257A (es) 2018-04-20
MX386334B MX386334B (es) 2025-03-18

Family

ID=56027234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014257A MX386334B (es) 2015-05-12 2016-05-11 Cèlulas t y sus usos en el tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr.

Country Status (18)

Country Link
US (1) US10568908B2 (es)
EP (1) EP3294304B1 (es)
JP (2) JP7284556B2 (es)
KR (1) KR102666781B1 (es)
CN (1) CN107835690A (es)
AR (1) AR104598A1 (es)
AU (1) AU2016262484B2 (es)
BR (1) BR112017024431B1 (es)
CA (1) CA2984178C (es)
CL (1) CL2017002846A1 (es)
FR (1) FR23C1025I2 (es)
IL (1) IL255581B (es)
MX (1) MX386334B (es)
NZ (1) NZ736675A (es)
PH (1) PH12017501993A1 (es)
RU (1) RU2720245C2 (es)
WO (1) WO2016183153A1 (es)
ZA (1) ZA201707335B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809542XA (en) 2016-05-25 2018-12-28 Council Queensland Inst Medical Res Methods of immunotherapy
EP3512531A4 (en) * 2016-09-16 2020-03-11 Baylor College of Medicine VIRUS-SPECIFIC T-CELL ACTIVATION AND EXPANSION PLATFORM
WO2019083866A1 (en) 2017-10-23 2019-05-02 Atara Biotherapeutics, Inc. METHODS FOR ADJUSTING IMMUNOTHERAPY MANAGEMENT TUMORAL FLOOD MANAGEMENT
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
WO2019136379A1 (en) * 2018-01-08 2019-07-11 Atara Biotherapeutics, Inc. Systems and methods for distributing cell therapies
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
KR20220092905A (ko) * 2019-10-23 2022-07-04 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 입양 면역요법
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
WO2004093905A1 (en) * 2003-04-16 2004-11-04 City Of Hope Human cytomegalovirus antigens expressed in mva and methods of use
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
US9738872B2 (en) 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
WO2012031132A1 (en) 2010-09-01 2012-03-08 Baylor College Of Medicine Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
US9931359B2 (en) * 2012-05-08 2018-04-03 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
JP2015533366A (ja) * 2012-10-19 2015-11-24 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 改良されたヒトヘルペスウイルス免疫療法
CA2926859A1 (en) * 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
NZ731321A (en) * 2014-11-05 2022-09-30 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Also Published As

Publication number Publication date
RU2017143151A (ru) 2019-06-13
BR112017024431A2 (pt) 2018-07-24
HK1244697A1 (en) 2018-08-17
RU2720245C2 (ru) 2020-04-28
BR112017024431B1 (pt) 2021-10-13
JP2021119154A (ja) 2021-08-12
US20180125891A1 (en) 2018-05-10
AU2016262484A1 (en) 2018-01-04
JP2018520095A (ja) 2018-07-26
CL2017002846A1 (es) 2018-05-25
PH12017501993A1 (en) 2018-03-26
AR104598A1 (es) 2017-08-02
RU2017143151A3 (es) 2019-10-29
IL255581B (en) 2021-03-25
ZA201707335B (en) 2021-02-24
US10568908B2 (en) 2020-02-25
FR23C1025I1 (fr) 2023-07-21
KR102666781B1 (ko) 2024-05-20
WO2016183153A1 (en) 2016-11-17
KR20180003575A (ko) 2018-01-09
FR23C1025I2 (fr) 2025-04-18
EP3294304A1 (en) 2018-03-21
NZ736675A (en) 2023-03-31
IL255581A (en) 2018-01-31
EP3294304B1 (en) 2020-01-29
MX386334B (es) 2025-03-18
CA2984178A1 (en) 2016-11-17
JP7284556B2 (ja) 2023-05-31
AU2016262484B2 (en) 2021-10-21
CN107835690A (zh) 2018-03-23
CA2984178C (en) 2023-10-31

Similar Documents

Publication Publication Date Title
MX2017014257A (es) Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t.
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
MX376190B (es) PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO.
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
CL2017002904A1 (es) Métodos y kits para tratar la depresión
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
MX2020005235A (es) Celula humana transformada y uso de la misma.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
CR20150638A (es) Marcador para trastornos de la esfingomielinasa ácida y sus usos
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
BR112021021787A2 (pt) Terapias de combinação
CO2017013361A2 (es) Angiogénesis usando células madre placentarias estimuladas
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
DOP2017000121A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro